Jaguar Health Enters Non-dilutive Binding Term Sheet for $6.0 Million Sale of Partial Rights to Possible Tropical Disease Priority Review Voucher
Jaguar Health announced a $6 million non-dilutive financing arrangement involving the sale of partial rights to a Tropical Disease Priority Review Voucher (TDPRV). This financing aims to support the clinical development of lechlemer for alleviating diarrhea in cholera patients. The TDPRV, previously valued between $67 million and $350 million, incentivizes drug development for neglected and rare diseases. The company has established that funds from this deal will fully cover the lechlemer clinical program, which is expected to advance clinical trials following positive initial studies.
- Secured $6 million non-dilutive financing through the sale of TDPRV rights, enhancing liquidity.
- Funding expected to fully support clinical development of lechlemer for cholera-related diarrhea.
- Potential market value for TDPRV could range from $67 million to $350 million, indicating significant future revenue potential.
- Investor entitled to 18% of TDPRV sales, indicating a profit-sharing arrangement that could dilute returns.
- If clinical trials do not start by July 1, 2022, or fail to meet endpoints, the company faces a serious financial penalty.
This additional non-dilutive financing will support development program for lechlemer for the indication of the symptomatic relief of diarrhea and dehydration in cholera patients
REMINDER: Jaguar-hosted investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time. Webcast registration and participation link appears below
SAN FRANCISCO, CA / ACCESSWIRE / January 13, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the Company has entered a binding agreement of terms (the "Term Sheet") for
Priority review vouchers are transferable and, in past transactions by other companies, have sold for prices ranging from
"We at Jaguar and Napo find it very rewarding to work in the pharmaceutical industry and be in a position to possibly help address such an important global health need and meet stakeholder expectations," stated Lisa Conte, Jaguar's founder, president, and CEO, "and we are thankful to the FDA for creating the priority review voucher program in an effort to drive development of drugs to benefit patients suffering from serious but often neglected diseases."
"We believe the funds generated by the proposed transaction described in the Term Sheet will fully fund clinical development of lechlemer for the cholera-related indication. Moving this second-generation anti-secretory agent into clinical development gives the Company ‘another shot on goal' - and we believe that lechlemer, which has the same mechanism of action as crofelemer and is significantly less costly to produce, may support development efforts to receive a TDPRV and provide long-term pipeline management of the novel anti-secretory mechanism of action of both crofelemer and lechlemer. Proof of concept trial design was achieved with a study in cholera patients with crofelemer at the renowned International Centre for Diarrhoeal Disease Research (icddr,b) in Bangladesh."
Per the terms of the Term Sheet, the Note shall bear interest at prime per annum, and interest shall be prepaid each 12 months at the beginning of the period. The Note shall be due 48 months after its issue date. While the Note is outstanding, the Investor shall be entitled to
In the event that, prior to redeeming the Note, the Company abandons the clinical trial with lechlemer for an indication of the symptomatic relief of diarrhea in cholera patients (such abandonment, which is deemed to include (i) failure to start the Phase 1 clinical trial by July 1, 2022 or (ii) failure to meet all primary endpoints in the pivotal trial with statistical significance, "Trial Default"), then, at Investor's sole election, the Company will immediately pay to Investor an amount equal to
Priority review vouchers are granted by the U.S. Food and Drug Administration (FDA) as an incentive to develop treatments for neglected diseases and rare diseases. The voucher entitles the bearer to regulatory review by the FDA in approximately six months rather than the standard ten months. The FDA awards a priority review voucher following approval of a treatment for a neglected disease, rare pediatric disease, or medical countermeasure.
Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae. According to the Centers for Disease Control and Prevention of the U.S. Department of Health & Human Services, an estimated 3‑5 million cholera cases and more than 100,000 cholera-related deaths occur each year around the world. The infection is often mild or without symptoms but can sometimes be severe. Approximately one in 10 of infected persons will have severe disease characterized by profuse watery diarrhea, vomiting, and leg cramps. In these people, rapid loss of body fluids leads to dehydration and shock. Without treatment, death can occur within hours. The largest cholera outbreak in recorded history recently occurred in Yemen. According to Oxfam, the number of cholera cases in Yemen in 2019 was the second largest ever recorded in a country in a single year, surpassed only by the numbers in Yemen in 2017. According to the Brookings Institution, cholera continues to spread in Yemen, with 180,000 new cases reported in the first eight months of 2020.
As recently announced, Napo is receiving preclinical services support from the National Institute of Allergy and Infectious Diseases (NIAID) for a 28-day preclinical toxicology and safety study in dogs that was initiated January 6, 2021 for lechlemer for the proposed cholera-related indication. NIAID is part of the National Institutes of Health. Under NIAID's suite of preclinical services, NIAID-funded contractors are conducting the dog study. As previously announced, a 28-day preclinical toxicology study in rats to support lechlemer development for the symptomatic relief of diarrhea from cholera was initiated in July of last year. Under NIAID's suite of preclinical services, NIAID-funded contractors also conducted the initial 7-day dog and rat toxicology studies, and completion of these shorter studies allowed for initiation of the longer-term, 28-day, IND-enabling toxicity studies.
Lechlemer is a drug candidate under the botanical guidance of the FDA. It is a standardized and proprietary Napo botanical extract that is distinct from crofelemer, the active pharmaceutical agent in Mytesi®, the Company's FDA-approved drug product. Lechlemer is sustainably derived from the same source as Mytesi: the Croton lechleri tree.
Participation Instructions for Jaguar Investor Webcast
When: Thursday, January 14 at 11:30 a.m. Eastern Time
Participant Registration & Access Link: Click Here
Mytesi (crofelemer delayed release tablets), the only oral plant-based prescription medicine approved under FDA Botanical Guidance, is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. Mytesi is a non-opiate chloride ion channel modulating antidiarrheal medicine that is approved in the U.S. by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
About Jaguar Health, Inc. and Napo Pharmaceuticals, Inc.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.
For more information about Jaguar, please visit https://jaguar.health. For more information about Napo, visit www.napopharma.com.
About Mytesi®
Mytesi® (crofelemer delayed release tablets) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (
More information and complete Prescribing Information are available at Mytesi.com. Crofelemer, the active ingredient in Mytesi®, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Napo's plans to pursue a TDPRV for the development of lechlemer for the indication of the symptomatic relief of diarrhea in cholera patients, the Company's belief that the funds generated by the proposed transaction described in the Term Sheet will fully fund clinical development of lechlemer for the cholera-related indication, the Company's belief that lechlemer may support development efforts to receive a TDPRV and provide long-term pipeline management of the novel anti-secretory mechanism of action of both crofelemer and lechlemer, and the Company's plan to host an investor webcast on January 14, 2021. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View source version on accesswire.com:
https://www.accesswire.com/624107/Jaguar-Health-Enters-Non-dilutive-Binding-Term-Sheet-for-60-Million-Sale-of-Partial-Rights-to-Possible-Tropical-Disease-Priority-Review-Voucher
FAQ
What is the purpose of Jaguar Health's recent $6 million financing?
What is a Tropical Disease Priority Review Voucher (TDPRV)?
What percentage of the TDPRV sales will Jaguar Health share with the investor?
When is the investor webcast hosted by Jaguar Health?
What are the potential financial implications of failing to meet clinical trial deadlines?
